Total Payments
$1,307
2024 Payments
$280.71
Companies
12
Transactions
57
Medicare Patients
12,488
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$1,061 (81.2%)
Education$245.89 (18.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,061 | 54 | 81.2% |
| Education | $245.89 | 3 | 18.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $276.12 | 5 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $256.18 | 32 | $0 (2019) |
| Novo Nordisk Inc | $251.11 | 3 | $0 (2024) |
| Medtronic Vascular, Inc. | $200.45 | 4 | $0 (2020) |
| Medtronic, Inc. | $189.60 | 5 | $0 (2024) |
| Bardy Diagnostics, Inc. | $25.00 | 1 | $0 (2019) |
| PFIZER INC. | $24.55 | 2 | $0 (2020) |
| Amarin Pharma Inc. | $22.66 | 1 | $0 (2020) |
| Allergan Inc. | $17.84 | 1 | $0 (2018) |
| BIOTRONIK INC. | $17.26 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $280.71 | 5 | Novo Nordisk Inc ($116.00) |
| 2023 | $180.17 | 3 | Novo Nordisk Inc ($116.00) |
| 2022 | $13.89 | 1 | AstraZeneca Pharmaceuticals LP ($13.89) |
| 2021 | $100.18 | 2 | E.R. Squibb & Sons, L.L.C. ($53.03) |
| 2020 | $111.80 | 5 | Medtronic Vascular, Inc. ($45.48) |
| 2019 | $265.99 | 19 | Novartis Pharmaceuticals Corporation ($127.17) |
| 2018 | $223.99 | 18 | Novartis Pharmaceuticals Corporation ($117.00) |
| 2017 | $130.25 | 4 | Medtronic Vascular, Inc. ($56.42) |
All Payment Transactions
57 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $69.17 | General |
| Category: Cardiovascular | ||||||
| 10/19/2024 | Medtronic, Inc. | VENASEAL (Device) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: EndoVenous Therapies | ||||||
| 09/27/2024 | BIOTRONIK INC. | BIOMONITOR (Device) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/19/2024 | Medtronic, Inc. | MYCARELINK (Device) | Food and Beverage | In-kind items and services | $63.25 | General |
| Category: Cardiac Diagnostics and Monitoring | ||||||
| 03/14/2024 | Novo Nordisk Inc | Ozempic (Drug) | Education | In-kind items and services | $116.00 | General |
| Category: Diabetes | ||||||
| 07/22/2023 | Medtronic, Inc. | CLOSUREFAST (Device) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: EndoVenous Therapies | ||||||
| 07/11/2023 | Medtronic, Inc. | AZURE XT DR MRI SURESCAN (Device) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Pacemakers | ||||||
| 06/27/2023 | Novo Nordisk Inc | Ozempic (Drug) | Education | In-kind items and services | $116.00 | General |
| Category: Diabetes | ||||||
| 10/13/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Education | In-kind items and services | $13.89 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/17/2021 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $53.03 | General |
| Category: Cardiovascular | ||||||
| 06/17/2021 | Medtronic, Inc. | CareLink (Device) | Food and Beverage | In-kind items and services | $47.15 | General |
| Category: Cardiac Diagnostics and Monitoring | ||||||
| 10/17/2020 | Medtronic Vascular, Inc. | CareLink Express (Device) | Food and Beverage | In-kind items and services | $45.48 | General |
| Category: Cardiac Diagnostics and Monitoring | ||||||
| 07/15/2020 | PFIZER INC. | ELIQUIS (Drug), VYNDAQEL | Food and Beverage | In-kind items and services | $12.52 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 04/28/2020 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: Cardiovascular | ||||||
| 04/23/2020 | PFIZER INC. | ELIQUIS (Drug), VYNDAQEL | Food and Beverage | In-kind items and services | $12.03 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 04/10/2020 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS, Tresiba | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Diabetes | ||||||
| 12/06/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $6.79 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $6.68 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/01/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $6.64 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/11/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $9.12 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/21/2019 | Medtronic Vascular, Inc. | CareLink Express (Device) | Food and Beverage | In-kind items and services | $62.50 | General |
| Category: Cardiac Diagnostics and Monitoring | ||||||
| 09/20/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $9.55 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/23/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $8.08 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/02/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $9.29 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/19/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $6.30 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 2,792 | 4,347 | $858,833 | $281,276 |
| 2022 | 33 | 3,002 | 4,516 | $866,132 | $287,373 |
| 2021 | 38 | 3,341 | 5,031 | $1.1M | $357,635 |
| 2020 | 35 | 3,353 | 5,002 | $995,845 | $312,689 |
Total Patients
12,488
Total Services
18,896
Medicare Billing
$1.2M
Procedure Codes
139
All Medicare Procedures & Services
139 procedure records from CMS Medicare Utilization — Page 3 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93284 | Programming of multiple lead implantable defibrillator system | Office | 2022 | 19 | 37 | $6,475 | $1,856 | 28.7% |
| 93285 | Programming of cardiac rhythm monitor system | Office | 2022 | 21 | 39 | $3,159 | $1,825 | 57.8% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2022 | 16 | 18 | $10,764 | $1,532 | 14.2% |
| 93291 | Evaluation of cardiac rhythm monitor system | Office | 2022 | 21 | 39 | $2,730 | $1,493 | 54.7% |
| 93660 | Evaluation of heart function using tilt table | Office | 2022 | 13 | 13 | $3,952 | $1,260 | 31.9% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2022 | 14 | 15 | $4,530 | $1,248 | 27.6% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2022 | 22 | 63 | $3,150 | $1,248 | 39.6% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 99 | 100 | $7,500 | $1,214 | 16.2% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2022 | 22 | 63 | $3,276 | $1,083 | 33.0% |
| 93272 | Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | Office | 2022 | 49 | 50 | $2,450 | $907.29 | 37.0% |
| 95921 | Testing of autonomic nervous system function and heart rate response to deep breathing | Office | 2022 | 13 | 13 | $2,093 | $800.11 | 38.2% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2022 | 38 | 53 | $2,915 | $749.94 | 25.7% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2022 | 20 | 29 | $3,741 | $662.20 | 17.7% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2022 | 19 | 25 | $1,625 | $485.16 | 29.9% |
| 93270 | Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring | Office | 2022 | 48 | 49 | $1,127 | $299.17 | 26.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 609 | 1,119 | $227,381 | $94,901 | 41.7% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 290 | 308 | $124,124 | $43,498 | 35.0% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Office | 2021 | 117 | 120 | $113,160 | $42,983 | 38.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 289 | 390 | $53,499 | $25,596 | 47.8% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2021 | 112 | 456 | $68,400 | $21,230 | 31.0% |
| 93880 | Ultrasound scanning of blood flow (outside the brain) on both sides of head and neck | Office | 2021 | 119 | 120 | $56,640 | $16,981 | 30.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 137 | 137 | $43,155 | $15,779 | 36.6% |
| 93656 | Evaluation and insertion of catheters for recording, pacing, and treatment of abnormal heart rhythm | Facility | 2021 | 11 | 12 | $18,000 | $11,046 | 61.4% |
| 33249 | Insertion or replacement of single or dual chamber pacing defibrillator leads | Facility | 2021 | 13 | 14 | $26,068 | $10,530 | 40.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 42 | 147 | $20,286 | $8,323 | 41.0% |
About Dr. Ashraf Koraym, MD
Dr. Ashraf Koraym, MD is a Clinical Cardiac Electrophysiology healthcare provider based in Beavercreek, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1760471692.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ashraf Koraym, MD has received a total of $1,307 in payments from pharmaceutical and medical device companies, with $280.71 received in 2024. These payments were reported across 57 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($1,061).
As a Medicare-enrolled provider, Koraym has provided services to 12,488 Medicare beneficiaries, totaling 18,896 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 139 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical Cardiac Electrophysiology
- Other Specialties Cardiovascular Disease
- Location Beavercreek, OH
- Active Since 10/13/2005
- Last Updated 06/04/2013
- Taxonomy Code 207RC0001X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1760471692
Products in Payments
- ENTRESTO (Drug) $256.18
- Ozempic (Drug) $251.11
- ELIQUIS (Drug) $231.50
- CareLink Express (Device) $107.98
- CAMZYOS (Drug) $69.17
- MYCARELINK (Device) $63.25
- Claria MRI (Device) $56.42
- AZURE XT DR MRI SURESCAN (Device) $50.00
- CareLink (Device) $47.15
- Reveal LINQ (Device) $36.05
- Carnation Ambulatory Monitor (Device) $25.00
- Vascepa (Drug) $22.66
- BYSTOLIC (Drug) $17.84
- BIOMONITOR (Device) $17.26
- VENASEAL (Device) $15.03
- CLOSUREFAST (Device) $14.17
- FARXIGA (Drug) $13.89
- ZONTIVITY (Drug) $12.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.